Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04314401 · ClinicalTrials.gov registry record

National Cancer Institute "Cancer Moonshot Biobank"

A clinical trial of Acute Myeloid Leukemia and Anatomic Stage III Breast Cancer AJCC v8, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
1,600
Enrollment target
20
Study locations

NCT04314401: Recruiting study of Acute Myeloid Leukemia and Anatomic Stage III Breast Cancer AJCC v8, sponsored by National Cancer Institute (NCI).

NCT04314401 is a study of Acute Myeloid Leukemia and Anatomic Stage III Breast Cancer AJCC v8 that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 1,600 participants, above the 111-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (1341% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04314401, a study of Acute Myeloid Leukemia and Anatomic Stage III Breast Cancer AJCC v8, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
1,600 participants
Enrollment target
20
Study locations

Study Summary

This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.

Primary Outcome

Will procure, store and distribute longitudinal biospecimens and associated clinical data for current and future cancer research in order to elucidate molecular mechanisms of sensitivity and intrinsic or acquired resistance to standard of care systemic therapies, including immunotherapy. Cases will be grouped according to patient demographics, cancer type and treatment regimen. Statistical analysis will be descriptive and will be analyzed for each Biospecimen Source Site (BSS) as well as study a

Conditions Studied

Acute Myeloid Leukemia Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Hormone Receptor-Positive Breast Carcinoma Clinical Stage IV Gastric Cancer AJCC v8 Esophageal Carcinoma Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Fallopian Tube Carcinoma Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 Gastric Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • OTHER Medical Chart Review
  • PROCEDURE Paracentesis

Study Locations (20)

Colorado

  • Intermountain Health Platte Valley Hospital - Brighton
  • Saint Joseph Hospital - Cancer Centers of Colorado - Denver
  • Lutheran Hospital - Cancer Centers of Colorado - Golden
  • Saint Mary's Hospital and Regional Medical Center - Grand Junction
  • Good Samaritan Hospital - Cancer Centers of Colorado - Lafayette

Alabama

  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis - Daphne
  • Thomas Hospital - Fairhope
  • Mobile Infirmary Medical Center - Mobile
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland - Saraland

California

  • PCR Oncology - Arroyo Grande
  • AIS Cancer Center at San Joaquin Community Hospital - Bakersfield
  • Veterans Affairs Loma Linda Healthcare System - Loma Linda
  • Salinas Valley Memorial - Salinas

Delaware

  • Bayhealth Hospital Kent Campus - Dover
  • Bayhealth Hospital Sussex Campus - Milford

Florida

  • Boca Raton Regional Hospital - Boca Raton
  • Broward Health North - Deerfield Beach

Arizona

  • Kingman Regional Medical Center - Kingman

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith

Connecticut

  • Hartford Hospital - Hartford

Trial Details

FieldValue
Enrollment Target 1,600 participants
Start Date 2020-11-11
Est. Completion 2027-04-30
National Cancer Institute (NCI)

3,257 total trials

What NCT04314401 shows while recruiting

NCT04314401 is an observational study that tracks outcomes without assigning an intervention. Its 1,600 participants enrollment target places it among the larger protocols in the corpus, above the 111-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (1341% higher).

The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT04314401 names 20 study sites across 8 states, led by Colorado, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT04314401 about?

NCT04314401 is a clinical study titled "National Cancer Institute "Cancer Moonshot Biobank"". This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking a...

What is the current status of trial NCT04314401?

This trial is currently recruiting. The enrollment target is 1,600 participants. The study started on 2020-11-11. Estimated completion is 2027-04-30.

What conditions does trial NCT04314401 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma, Clinical Stage IV Gastric Cancer AJCC v8.

What interventions are being tested in trial NCT04314401?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Medical Chart Review (OTHER), Paracentesis (PROCEDURE).

Who is sponsoring clinical trial NCT04314401?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04314401 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04314401's enrollment target sits among peer trials

1,600 4th of 306 higher than 303 of 306 other Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00646022 · 1,600 participants

    Natural History of Familial Carcinoid Tumor

  • NCT03109197 · 1,600 participants

    Sudden Unexplained Death in Childhood (SUDC) Registry

  • NCT03511118 · 1,600 participants

    Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

  • NCT04580472 · 1,600 participants · Phase 4

    Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04314401

Source: ClinicalTrials.gov NCT04314401, the US trial registry maintained by the National Library of Medicine. NCT04314401 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.